Viral lymphomagenesis

Current Opinion in Hematology

Volumn 13, Issue 4, 2006, Pages 254-259

  Ahmed, Nabil ^a   Heslop, Helen E ^a,b  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b CENTER FOR CELL AND GENE THERAPY   (United States)

Author keywords

Epstein Barr virus; Hepatitis C; Human herpes virus 8; Lymphomagenesis

Indexed keywords

ACICLOVIR; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; DOXORUBICIN; GANCICLOVIR; GEMCITABINE; INTERFERON; PEGINTERFERON; RIBAVIRIN; RITUXIMAB;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIGEN SPECIFICITY; B CELL LYMPHOMA; CARCINOGENESIS; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HODGKIN DISEASE; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN T CELL LEUKEMIA VIRUS 1; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOCOMPETENCE; IMMUNOMODULATION; IMMUNOTHERAPY; LATENT PERIOD; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; REVIEW; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE; VIRUS GENOME; VIRUS REPLICATION;

ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; CELL TRANSFORMATION, VIRAL; GENOME, VIRAL; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOTHERAPY, ADOPTIVE; LYMPHOMA; ONCOGENIC VIRUSES; TUMOR VIRUS INFECTIONS;

EID: 33747878593     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/01.moh.0000231423.38525.fe     Document Type: Review

References (56)

1. Young LS, Rickinson AB. Epstein-Barr virus 40 years on. Nat Rev Cancer 2004; 4:757-768.
2. Thorley-Lawson DA, Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med 2004; 350:1328-1337.
3. Gottschalk S, Rooney CM, Heslop HE. Post-transplant lymphoproliferative disorders. Annu Rev Med 2005; 56:29-44. Review that discusses the clinicopathological features of different forms of PTLD, the state of art in management and the recent advances in the therapeutic options available.
4. Dupre L, Andolfi G, Tangye SG, et al. SAP controls the cytolytic activity of CD8+ T cells against EBV-infected cells. Blood 2005; 105:4383-4389. Study showing that SAP-deficient CTLs from patients with XLP and hemophagocytic lymphohistiocytosis display a specific lytic defect against autologous and allogeneic EBV-positive B cells. This defect is associated with the defective polarization of 2B4, perforin, and lipid rafts at the contact area of CTLs with EBV-positive targets
5. Nichols KE, Hom J, Gong SY, et al. Regulation of NKT cell development by SAP, the protein defective in XLP. Nat Med 2005; 11:340-345. Shows that absence of NKT cells may contribute to the phenotypes of SAP deficiency, including abnormal antiviral and antitumor immunity and hypogammaglobulinemia.
6. Feng WH, Cohen JI, Fischer S, et al. Reactivation of latent Epstein-Barr virus by methotrexate a potential contributor to methotrexate-associated lymphomas. J Natl Cancer Inst 2004; 96:1691-1702.
7. Voo KS, Fu T, Wang HY, et al. Evidence for the presentation of major histocompatibility complex class I-restricted Epstein-Barr virus nuclear antigen 1 peptides to CD8+ T lymphocytes. J Exp Med 2004; 199:459-470.
8. Levitskaya J, Coram M, Levitsky V, et al. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 1995; 375:685-688.
9. Keegan TH, Glaser SL, Clarke CA, et al. Epstein-Barr virus as a marker of survival after Hodgkin's lymphoma: a population-based study. J Clin Oncol 2005; 23:7604-7613. Epidemiology study showing that EBV tumor cell presence in Hodgkin's disease is associated with better survival in young patients and poorer survival in older patients independent of other factors.
10. Jarrett RF, Stark GL, White J, et al. Impact of tumor Epstein-Barr virus status on presenting features and outcome in age-defined subgroups of patients with classic Hodgkin lymphoma a population-based study. Blood 2005; 106:2444-2451. Epidemiology study showing that impact of EBV status in Hodgkin's disease varied with age at diagnosis. In young patients, EBV-associated cases had a survival advantage but in patients 50 years or older, EBV positivity was associated with a significantly poorer outcome.
11. Diepstra A, Niens M, Vellenga E, et al. Association with HLA class I in Epstein-Barr-virus-positive and with HLA class III in Epstein-Barr-virus- negative Hodgkin's lymphoma. Lancet 2005; 365:2216-2224. Study showing that areas within the HLA class I regions are associated with susceptibility to EBV-positive Hodgkin's disease. The association of EBV-positive Hodgkin's lymphoma with HLA class I suggests that this polymorphism might affect the proper presentation of EBV antigens to cytotoxic T lymphocytes or the quality of the immune response.
12. Brauninger A, Schmitz R, Bechtel D, et al. Molecular biology of Hodgkin's and Reed/Sternberg cells in Hodgkin's lymphoma. Int J Cancer 2005. Useful summary of aberrantly activated signaling pathways and transcription factors that contribute to the rescue of Hodgkin's and Reed/Sternberg cells from apoptosis.
13. Bechtel D, Kurth J, Unkel C, Kuppers R. Transformation of BCR-deficient germinal-center B cells by EBV supports a major role of the virus in the pathogenesis of Hodgkin and posttransplantation lymphomas. Blood 2005; 106:4345-4350. In-vitro study that supports the idea that EBV plays a central role in the pathogenesis of Hodgkin's disease by rescuing B-cell receptor-deficient, preapoptotic germinal center B cells from apoptosis, and that EBV infection renders the cells independent from survival signals normally supplied by a BCR.
14. Mancao C, Altmann M, Jungnickel B, Hammerschmidt W. Rescue of 'crippled' germinal center B cells from apoptosis by Epstein-Barr virus. Blood 2005; 106:4339-4344. This study also implies an important role for EBV in the process of lymphomagenesis in certain cases of Hodgkin's disease. The authors show that B-cell receptor-negative germinal center B cells with deleterious mutations enter the cell cycle upon infection with EBV in vitro and yield clonal lymphoblastoid cell lines.
15. Poppema S. Immunobiology and pathophysiology of Hodgkin lymphomas. Hematology 2005; 231-238. An excellent review of tumor evasion mechanisms in Hodgkin's disease.
16. Heslop HE. Biology and treatment of Epstein-Barr virus-associated nonHodgkin lymphomas. Hematology (Am Soc Hematol Educ Program) 2005; 260-266. An overview of EBV-positive NHL.
17. Nava VE, Jaffe ES. The pathology of NK-cell lymphomas and leukemias. Adv Anat Pathol 2005; 12:27-34. An excellent overview of natural killer cell lymphomas, many of which are EBV-positive.
18. O'Reilly RJ, Small TN, Papadopoulos E, et al. Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts. Immunol Rev 1997; 157:195-216.
19. Rooney CM, Smith CA, Ng CYC, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998; 92:1549-1555.
20. Gustafsson A, Levitsky V, Zou JZ, et al. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease prophylactic infusion of EBV-specific cytotoxic T cells. Blood 2000; 95:807-814.
21. Haque T, Amlot PL, Helling N, et al. Reconstitution of EBV-specific T cell immunity in solid organ transplant recipients. J Immunol 1998; 160:6204-6209.
22. Comoli P, Labirio M, Basso S, et al. Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood 2002; 99:2592-2598.
23. Haque T, Wilkie GM, Taylor C, et al. Treatment of Epstein-Barr-virus- positive posttransplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet 2002; 360:436-442.
24. Sun Q, Burton R, Reddy V, Lucas KG. Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma. Br J Haematol 2002; 118:799-808.
25. Bollard CM, Aguilar L, Straathof KC, et al. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J Exp Med 2004; 200:1623-1633.
26. Straathof KC, Leen AM, Buza EL, et al. Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma. J Immunol 2005; 175:4137-4147. Reports the detailed epitope specificities of LMP2-directed immune responses in CTL lines from patients with Hodgkin's disease using a peptide library that spans the entire LMP2 protein. Nine new LMP2-derived HLA class I and class II-restricted epitopes were identified.
27. Lucas KG, Salzman D, Garcia A, Sun Q. Adoptive immunotherapy with allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes for recurrent, EBV-positive Hodgkin disease. Cancer 2004; 100:1892-1901.
28. Cho HI, Hong YS, Lee MA, et al. Adoptive transfer of Epstein-Barr virus-specific cytotoxic T-lymphocytes for the treatment of angiocentric lymphomas. Int J Hematol 2006; 83:66-73.
29. Israel BF, Gulley M, Elmore S, et al. Anti-CD70 antibodies a potential treatment for EBV+ CD70-expressing lymphomas. Mol Cancer Ther 2005; 4:2037-2044. CD70 is expressed on highly activated lymphocytes and this study shows that monoclonal antibodies directed against human kill EBV+ B cells in vitro and also inhibited the growth of CD70+ Burkitt's lymphoma cells in a SCID mouse model.
30. Feng WH, Hong G, Delecluse HJ, Kenney SC. Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas. J Virol 2004; 78:1893-1902.
31. Farrell CJ, Lee JM, Shin EC, et al. Inhibition of Epstein-Barr virus-induced growth proliferation by a nuclear antigen EBNA2-TAT peptide. Proc Natl Acad Sci USA 2004; 101:4625-4630.
32. Nasimuzzaman M, Kuroda M, Dohno S, et al. Eradication of Epstein-Barr virus episome and associated inhibition of infected tumor cell growth by adenovirus vector-mediated transduction of dominant-negative EBNA1. Mol Ther 2005; 11:578-590. Shows that a mutant EBNA1 can act as a dominant-negative effector that efficiently impedes the EBV-dependent malignant phenotypes in cells regardless of viral latency or tissue origin.
33. Katano H, Pesnicak L, Cohen JI. Simvastatin induces apoptosis of Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines and delays development of EBV lymphomas. Proc Natl Acad Sci U S A 2004; 101:4960-4965.
34. Slobod KS, Taylor GH, Sandlund JT, et al. Epstein-Barr virus-targeted therapy for AIDS-related primary lymphoma of the central nervous system. Lancet 2000; 356:1493-1494.
35. Pakakasama S, Eames GM, Morriss MC, et al. Treatment of Epstein-Barr virus lymphoproliferative disease after hematopoietic stem-cell transplantation with hydroxyurea and cytotoxic T-cell lymphocytes. Transplantation 2004; 78:755-757.
36. Kasamon YL, Ambinder RF. AIDS-related primary central nervous system lymphoma. Hematol Oncol Clin North Am 2005; 19:665-667. Excellent review of EBV-positive CNS lymphomas in patients with HIV.
37. Piriou E, van Dort K, Nanlohy NM, et al. Loss of EBNA1-specific memory CD4+ and CD8+ T cells in HIV-infected patients progressing to AIDS-related non-Hodgkin lymphoma. Blood 2005; 106:3166-3174. Study suggesting that loss of EBNA1-specific T-cell immunity may be important for progression to NHL.
38. Diamond C. Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy. Cancer 2005; 103:650. This interesting work describes a retrospective analysis depicting the impact of HAART on the incidence and the types of HIV-related malignancies including response to therapy.
39. Bonnet F, Balestre E, Thiebaut R, et al. Factors associated with the occurrence of AIDS-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: Aquitaine Cohort, France. France Clin Infect Dis 2006; 42:411-417.
40. Bower M, Palmieri C, Dhillon T. AIDS-related malignancies changing epidemiology and the impact of highly active antiretroviral therapy. Curr Opin Infect Dis 2006; 19:14-19.
41. Piriou E, Jansen CA, Dort K, et al. Reconstitution of EBV latent but not lytic antigen-specific CD4+ and CD8+ T cells after HIV treatment with highly active antiretroviral therapy. J Immunol 2005; 175:2010-2017. Interesting study which shows that long-term HAART does not alter the EBV DNA load, but does lead to a restoration of EBNA1-specific CD4 and CD8 T-cell responses.
42. Carbone A, Gloghini A. AIDS-related lymphomas from pathogenesis to pathology. Br J Haematol 2005; 130:662-670. This is a reviewthat addresses AIDS-related lymphomas starting with a description of the pathologically heterogeneous entities currently related to HIV through the clinical feature and finally the possible molecular mechanisms involved in lymphomagenesis.
43. Simonelli C, Tedeschi R, Gloghini A, et al. Prognostic factors in human herpesvirus 8-related lymphoproliferative disorders associated with HIV infection. J Clin Oncol 2006; 24:209-210.
44. Mele A, Pulsoni A, Bianco E, et al. Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study. Blood 2003; 102:996-999.
45. Libra M, Gasparotto D, Gloghini A, et al. Hepatitis C virus (HCV) I hepatitis C virus (HCV) infection and lymphoproliferative disorders. Front Biosci 2005; 10:2460-2471. Good review of HCV and lymphomagenesis.
46. Levy S, Shoham T. The tetraspanin web modulates immune-signalling complexes. Nat Rev Immunol 2005; 5:136-148. This interesting article describes the tetraspanins, a family of surface receptors that are highly exploited by human pathogens. From this family, the role of CD81 is evolving strongly in the pathogenesis of HCV.
47. Nakajima H, Cocquerel L, Kiyokawa N, et al. Kinetics of HCV envelope proteins' interaction with CD81 large extracellular loop. Biochem Biophys Res Commun 2005; 328:1091-1100. Analysis of the kinetics of interactions between CD81 and HCV envelope proteins.
48. Cocquerel L, Kuo CC, Dubuisson J, Levy S. CD81-dependent binding of hepatitis C virus E1E2 heterodimers. J Virol 2003; 77:10677-10683.
49. Machida K, Cheng KT, Sung VM, et al. Hepatitis C virus induces a mutator phenotype: enhanced mutations of immunoglobulin and protooncogenes. Proc Natl Acad Sci USA 2004; 101:4262-4267.
50. Hermine O, Lefrere F, Bronowicki JP, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002; 347:89-94.
51. Vallisa D, Bernuzzi P, Arcaini L, et al. Role of antihepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: a multicenter Italian experience. J Clin Oncol 2005; 23:468-473. This is a multicenter study from Italy where the prevalence of HCV infection is relatively high, showing, in 13 patients, the advantage of antiviral treatment in patients affected by HCV-related, low-grade, B-cell NHL.
52. Taylor GP, Matsuoka M. Natural history of adult T-cell leukemia/lymphoma and approaches to therapy. Oncogene 2005; 24:6047-6057. Good review of HTLV1-associated lymphoma.
53. Harashima N, Tanosaki R, Shimizu Y, et al. Identification of two new HLA-A*1101-restricted tax epitopes recognized by cytotoxic T lymphocytes in an adult T-cell leukemia patient after hematopoietic stem cell transplantation. J Virol 2005; 79:10088-10092. Describes Tax-specific CTL expansion in peripheral blood mononuclear cells from post-HSCT ATL patients and identifies two new epitopes, Tax88-96 and Tax272-280, restricted by HLA-A11.
54. Paya CV, Fung JJ, Nalesnik MA, et al. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation 1999; 68:1517-1525.
55. Vilchez RA, Madden CR, Kozinetz CA, et al. Association between simian virus 40 and non-Hodgkin lymphoma. Lancet 2002; 359:817-823.
56. MacKenzie J, Wilson KS, Perry J, et al. Association between simian virus 40 DNA and lymphoma in the United Kingdom. J Natl Cancer Inst 2003; 95:1001-1003.